VITA 34 (V3V) AI Stock Analysis

VITA 34

(XETRA:V3V)

Select Model

Rating:43Neutral

Price Target:EUR 3.00▲(4.90% Upside)

Action:reiterated

Date:09/06/26

The overall score is heavily constrained by the company's weak financial foundation. While operational cash flow has improved, the balance sheet is critically leveraged with minimal equity, creating significant financial risk. The stock's technical posture shows a weak long-term trend, and the negative earnings make valuation metrics irrelevant. The primary risk is the company's ability to sustain its operational turnaround long enough to repair its balance sheet.

Positive Factors

Recurring biobanking revenueThe combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.

Negative Factors

Ongoing net lossesPersistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.

VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 48.46M
Dividend Yield: ―
Average Volume (3M): 1,346
Price to Earnings (P/E): -6.4
Beta (1Y): 0.15
Revenue Growth: 0.06%
EPS Growth: 22.85%
Country: Germany
Employees: 723
Sector: General
Sector Strength: 55
Industry: Biotechnology

VITA 34 Business Overview & Revenue Model

Company Description

VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therape...

How the Company Makes Money

VITA 34 makes money primarily by providing fee-based biobanking services for newborn stem cells. Its core revenue model is built on (1) up-front service fees charged for the collection kit, logistics, laboratory processing/testing, and initial cryopr...

VITA 34 Financial Statement Overview

Summary

Financial performance is mixed. Revenue growth is strong and cash flow has turned positive, but persistent net losses and a severely stressed balance sheet with dangerously high leverage and negative equity returns weigh heavily on the score.

Income Statement

45Neutral

Balance Sheet

25Negative

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	87.78M	88.17M	82.18M	77.06M	68.94M	28.42M
Gross Profit	54.13M	44.84M	20.65M	28.24M	2.73M	12.44M
EBITDA	5.65M	4.76M	-443.00K	5.81M	-18.34M	791.00K
Net Income	-7.67M	-6.30M	-12.14M	-1.86M	-27.39M	-3.93M
Balance Sheet
Total Assets	162.35M	168.26M	152.74M	158.36M	151.51M	177.95M
Cash, Cash Equivalents and Short-Term Investments	12.45M	11.88M	18.46M	17.42M	18.23M	35.26M
Total Debt	23.03M	23.51M	18.10M	21.57M	28.18M	32.32M
Total Liabilities	158.45M	162.84M	139.83M	135.58M	135.66M	136.00M
Stockholders Equity	5.05M	7.12M	14.13M	23.56M	16.50M	43.07M
Cash Flow
Free Cash Flow	4.32M	-249.00K	5.46M	5.06M	-10.92M	467.00K
Operating Cash Flow	7.14M	3.88M	8.65M	9.15M	-4.49M	2.73M
Investing Cash Flow	-7.82M	-12.66M	-3.08M	-3.57M	-5.81M	24.87M
Financing Cash Flow	1.61M	3.89M	-6.09M	-5.09M	-6.27M	-4.70M

VITA 34 Technical Analysis

Technical Analysis SentimentNegative

Last Price2.86

Price Trends

50DMA2.92Negative

100DMA3.05Negative

200DMA3.87Negative

Market Momentum

MACD-0.05Positive

RSI38.61Neutral

STOCH45.95Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Negative. The current price of 2.86 is below the 20-day moving average (MA) of 2.89, below the 50-day MA of 2.92, and below the 200-day MA of 3.87, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.61 is Neutral, neither overbought nor oversold. The STOCH value of 45.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:V3V.

VITA 34 Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:V3V against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:MED	64Neutral	EUR 251.75M	8.72	11.54%	0.75%	2.94%	-14.28%
DE:SBS	57Neutral	EUR 273.51M	-562.50	-0.17%	2.67%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:ILM1	55Neutral	EUR 269.85M	24.05	2.16%	―	9.88%	-38.44%
DE:V3V	43Neutral	EUR 48.46M	-6.41	-94.93%	―	0.06%	22.85%

* General Sector Average

Performance Comparison

DE:V3V and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:V3V	VITA 34	2.78	-2.52	-47.55%
DE:MED	MEDICLIN AG	5.30	1.68	46.37%
DE:SBS	STRATEC Biomedical	22.50	0.99	4.62%
DE:ILM1	Medios AG	10.58	-1.68	-13.70%
DE:HAEK	HAEMATO AG	12.70	3.48	37.73%
DE:7V0	Novogenia Holding AG	6.40	-0.22	-3.26%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

VITA 34 AI Stock Analysis